Related Experiment Videos

Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma

G Piot¹, J P Droz, C Theodore

¹Service de Médecine, Institut Gustave-Roussy, Villejuif, France.

|January 1, 1988

Abstract:

Sixteen patients with adult metastatic renal cell carcinoma were treated with elliptinium acetate, 80 mg/m2.day, for 3 consecutive days every 3 weeks. Among the 14 patients evaluable, no objective effects were observed. The toxicity was mild and no patients experienced intravascular hemolysis.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Breast cancer in a transgender man and hypofractionated radiotherapy: A case report and review of literature.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

ESMO open·2021

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

European journal of cancer (Oxford, England : 1990)·2017

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.

BMC cancer·2016

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs.

British journal of cancer·2015

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

See all related articles